We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study.
- Authors
Hochhaus, Andreas; le Coutre, Philipp D; Kantarjian, Hagop M; Baccarani, Michele; Erben, Philipp; Reiter, Andreas; McCulloch, Tracey; Fan, Xiaolin; Novick, Steven; Giles, Francis J
- Abstract
Hypereosinophilic syndrome (HES) and chronic eosinophilic leukemia (CEL) are characterized by sustained overproduction of eosinophils and organ dysfunction. CEL involves the presence of clonal genetic markers, such as a fusion of FIP1-like 1 protein and platelet-derived growth factor receptor α (FIP1L1-PDGFRα, or F/P) or PDGFRα-activating mutations.
- Publication
Journal of cancer research and clinical oncology, 2013, Vol 139, Issue 12, p1985
- ISSN
1432-1335
- Publication type
Journal Article
- DOI
10.1007/s00432-013-1529-7